Most 340B conversations start with HIV treatment — Biktarvy, Cabenuva, the high-cost antiretrovirals that generate the biggest savings gaps. But there's a quieter opportunity building right now in injectable PrEP that STD clinics and Ryan White programs should be paying attention to.
The savings per fill on injectable PrEP aren't eye-popping in isolation — roughly $150–$220 per administration at current 340B ceiling prices. But injectable PrEP isn't a one-time transaction. It's a recurring touchpoint on a fixed calendar. And that changes the math entirely.
Under the 340B program, covered entities pay the manufacturer's ceiling price — a formula tied to the Average Manufacturer Price (AMP) minus a statutory discount. For brand-name drugs like Apretude and Yeztugo, that ceiling typically lands 20–50% below WAC, and well below commercial reimbursement.
The savings spread — the gap between what you paid at 340B ceiling price and what you bill Medicaid, Medicare, or commercial insurance — is your margin. For both injectable PrEP drugs, that spread runs approximately $150–$220 per administration event at current pricing.
Illustrative 340B savings (Apretude, Medicaid):
Two hundred dollars per fill sounds modest. But injectable PrEP patients are not one-time customers. They come back — on a fixed schedule, prescribed by you, administered in your clinic. Every visit is a billable administration, a required HIV test, an STI screening opportunity, and another $200 in 340B savings.
When a patient starts Descovy or generic TDF/FTC, they pick up their prescription at a pharmacy. Your clinic interaction is the prescribing visit — maybe a quarterly check-in. The 340B savings, if captured at all, depend on contract pharmacy routing.
Injectable PrEP changes the structure of that relationship fundamentally. The drug is administered in your clinic. Every fill is a clinic visit. Every visit generates:
The patient is already there. The question is how many of those patients your clinic is scheduled to see — and whether you have the infrastructure to manage the injection calendar efficiently.
Apretude is an intramuscular (gluteal) injectable form of cabotegravir, an integrase strand transfer inhibitor (INSTI), FDA-approved December 2021 for HIV PrEP. It is administered every two months — making it the higher-frequency of the two injectable PrEP options currently on the market.
Full dosing schedule:
A patient who starts Apretude today will be in your clinic approximately 6 times per year for continuation injections. For 100 active Apretude patients, that's roughly 600 clinical encounters per year on a fixed schedule.
Yeztugo is a subcutaneous injectable form of lenacapavir, an HIV capsid inhibitor — FDA-approved June 2025 for HIV PrEP. It requires only two visits per year after initiation, making it the most convenient injectable PrEP regimen currently available.
In the Phase 3 PURPOSE 1 and PURPOSE 2 trials, Yeztugo demonstrated efficacy of 100% in cisgender women and 96% in a primarily male population — the highest efficacy ever demonstrated for a PrEP agent in clinical trials.
Full dosing schedule:
Clinical note: Yeztugo creates subcutaneous nodules at the injection site that can persist for a median of 183 days. These are generally painless and not visible, but patients should be counseled before initiation.
| Factor | Apretude (CAB-LA) | Yeztugo (LEN SC) |
|---|---|---|
| Drug class | INSTI (cabotegravir) | Capsid inhibitor (lenacapavir) |
| Route | Intramuscular (gluteal) | Subcutaneous (abdominal) |
| Initiation | Optional oral lead-in → Injection #1 → Injection #2 one month later | Day 1: 2 SC injections + 2 oral tablets. Day 2: 2 oral tablets. |
| Continuation interval | Every 2 months (±7 days) | Every 6 months (26 weeks ±2 weeks) |
| Clinic visits/year | ~6 visits | ~2 visits |
| Est. 340B savings/patient/year | ~$1,200 (6 × ~$200) | ~$400 (2 × ~$200) |
| Clinical trial efficacy | Superior to oral TDF/FTC (HPTN 083/084) | 100% in women (PURPOSE 1); 96% overall (PURPOSE 2) |
| Injection site reaction | Gluteal IM — 1 injection per visit | Abdominal SC — 2 injections; nodule may persist ~6 months |
| Real-world experience | 4+ years (approved Dec 2021) | Newly approved June 2025 |
| Patient support program | ViiVConnect / ViiV Healthcare PAP | Gilead Advancing Access |
Clinic workflow note: Apretude generates ~600 injection encounters/year for 100 patients; Yeztugo generates ~200. Both are valuable. Offering both lets patients self-select. Your clinic captures the 340B margin either way.
Real-world adherence to daily oral PrEP among high-risk populations consistently runs 40–60%. Injectable PrEP changes the adherence model completely — protection is baked into the appointment. As long as the patient comes to the clinic, they're protected.
Truvada (TDF/FTC) carries documented nephrotoxic and bone density effects. Neither Apretude nor Yeztugo carries these signals. For patients with renal concerns or who have struggled with TDF tolerability, injectables are a genuinely superior clinical option.
A daily pill bottle is a disclosure. An every-two-month or every-six-month appointment with their STD clinic is private. For patients navigating disclosure concerns, injectable PrEP can be the difference between accepting PrEP and declining it.
Oral PrEP patients churn — they miss refill windows, switch providers, stop filling prescriptions. Injectable PrEP patients have an appointment on the calendar. Your team has a contact date and a structured reason to reach out. Better retention means lower patient acquisition cost per active PrEP patient.
Yeztugo demonstrated 100% efficacy in cisgender women in PURPOSE 1 — compared to oral TDF/FTC, where tissue concentrations in the female genital tract are lower than in rectal tissue, creating a more demanding adherence threshold for women.
Injectable agents deliver systemic protection regardless of anatomy. The same injection that protects against anal exposure also protects against vaginal exposure, at the same concentration, for the same duration. For Ryan White programs serving cisgender women, transgender women, and nonbinary individuals, injectable PrEP removes the anatomical efficacy gap entirely.
Apretude's HPTN 084 trial, enrolling exclusively cisgender women in sub-Saharan Africa, demonstrated that cabotegravir every 2 months was significantly more effective than daily oral TDF/FTC in that population. Better adherence driven by fewer required actions produces better outcomes.
Both manufacturers have invested in removing access barriers. Understanding these programs is part of running an efficient injectable PrEP practice.
ViiVConnect (viivconnect.com) — ViiV's hub services platform for Apretude. Handles benefits verification, prior authorizations, specialty pharmacy coordination, and claims support. Includes Real-Time Benefit Verification and the APRETUDE Savings Program for eligible commercially insured patients.
ViiV Healthcare PAP — Operated through the GSK Patient Access Programs Foundation, provides Apretude at no cost to eligible uninsured patients.
Gilead Advancing Access (gileadadvancingaccess.com) — Covers commercially insured patients' out-of-pocket costs and provides Yeztugo free to income-eligible uninsured patients. Layers with 340B pricing for near-zero cost coverage for qualifying patients.
Important: Manufacturer assistance programs do not reduce your 340B savings. They reduce the patient's out-of-pocket. A fully uninsured patient who qualifies for Gilead Advancing Access can receive Yeztugo at no cost while your clinic still captures the 340B margin on the drug and bills the administration fee separately. Both are available simultaneously.
Injectable PrEP is still in early adoption at most STD clinics and Ryan White programs. That's a window. STD clinics that build the infrastructure now — injection scheduling, patient education, 340B optimization, manufacturer program enrollment — will be positioned to absorb the growth as Yeztugo's superior efficacy data drives guideline updates and payer coverage expansions over the next 24 months.
Medical disclaimer: This article is for healthcare marketing and operational strategy purposes. Drug pricing, 340B ceiling prices, and payer reimbursement rates change frequently — figures cited are illustrative. Consult your 340B program administrator before making clinical or formulary decisions. APRETUDE® is a trademark of ViiV Healthcare. YEZTUGO® is a trademark of Gilead Sciences, Inc.